[ad_1] MUNICH (Reuters) – An AstraZeneca drug blocking the ability of a cancer cell to repair its genetic code has significantly reduced the risk of ovarian cancer worsening in a phase III …
Read More »
[ad_1] Un traitement mis au point par AstraZeneca a montré de grands avantages pour les femmes récemment diagnostiquées du cancer de l’ovaire dans le cadre de la stratégie de croissance du fabricant …
Read More »[ad_1] By Anette Breindl, Senior Science Writer MUNICH – With more than three years of follow-up, median progression-free survival (PFS) has not yet been reached in the treatment group of the SOLO-1 …
Read More »